Bristol-Myers Squibb shares are trading lower after the company announced that its multiple myeloma candidate arlocabtagene autoleucel met primary and secondary endpoints in its phase II QUINTESSENTIAL trial. Investors may be taking pause after the results following an approximately 43% share price gain over the past year.